Approved Formulary
Webpage Links
QR Code Add Formweb to your mobile device
Android iOS
February P&T meeting minutes have been posted.
Approved Formulary
Search results for:

filgrastim

filgrastim
  • Therapeutic Substitutions Filgrastim / Pegfilgrastim Biosimilars
  • Cell Status NFISA
  • Exceptions / Designators Use restricted to adjunct treatment with Chemo, HIV, HCV and dialysis treatments
  • * Non-Formulary *
Brand names: Neupogen, Neupogen SingleJect
Form Strength  
SOLUTION, INJECTABLE 300 mcg/mL; 480 mcg/0.8 mL; 480 mcg/1.6 mL
Additional Information:

APRIL 2020 P&T MINUTES

JANUARY 2012 P&T MINUTES

DECEMBER 2011 P&T MINUTES

NOVEMBER 2010 P&T MINUTES

APRIL 2009 P&T MINUTES

MARCH 2009 P&T MINUTES

NOTE: This medication will be substituted by pharmacy with a biosimilar medication, which is an appropriate therapeutic substitution  per Filgrastim Therapeutic Substitution Protocol.

Last updated: Nov. 16, 2021

This site is intended for the staff of Oregon Department of Corrections.
While others may view accessible pages, Oregon Department of Corrections makes no warranty, express or implied,
as to the use of this information outside of Oregon Department of Corrections.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved